Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

2.

Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.

Kennedy SH, Andersen HF, Lam RW.

J Psychiatry Neurosci. 2006 Mar;31(2):122-31. Erratum in: J Psychiatry Neurosci. 2006 Jul;31(4):228.

3.

Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.

Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME.

Biol Psychiatry. 2008 Feb 15;63(4):424-34.

PMID:
17888885
6.

Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials.

Vis PM, van Baardewijk M, Einarson TR.

Ann Pharmacother. 2005 Nov;39(11):1798-807.

PMID:
16189284
7.

The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.

Bauer M, Tharmanathan P, Volz HP, Moeller HJ, Freemantle N.

Eur Arch Psychiatry Clin Neurosci. 2009 Apr;259(3):172-85. doi: 10.1007/s00406-008-0849-0.

PMID:
19165525
8.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
9.

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.

Thase ME, Entsuah AR, Rudolph RL.

Br J Psychiatry. 2001 Mar;178:234-41.

10.

Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.

Trivedi MH, Wan GJ, Mallick R, Chen J, Casciano R, Geissler EC, Panish JM.

J Clin Psychopharmacol. 2004 Oct;24(5):497-506.

PMID:
15349005
11.

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder.

Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS.

Ann Intern Med. 2005 Sep 20;143(6):415-26. Review.

PMID:
16172440
12.

Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability.

Kolevzon A, Mathewson KA, Hollander E.

J Clin Psychiatry. 2006 Mar;67(3):407-14. Review.

PMID:
16649827
13.

[Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents].

Bailly D.

Presse Med. 2006 Oct;35(10 Pt 2):1507-15. Review. French.

PMID:
17028514
14.
15.
16.

Screening for child and adolescent depression in primary care settings: a systematic evidence review for the US Preventive Services Task Force.

Williams SB, O'Connor EA, Eder M, Whitlock EP.

Pediatrics. 2009 Apr;123(4):e716-35. doi: 10.1542/peds.2008-2415. Review.

PMID:
19336361
17.

Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents.

Hetrick S, Merry S, McKenzie J, Sindahl P, Proctor M.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD004851. Review. Update in: Cochrane Database Syst Rev. 2012;11:CD004851.

PMID:
17636776
18.

[Use of antidepressant drugs in schizophrenic patients with depression].

Micallef J, Fakra E, Blin O.

Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. Review. French.

PMID:
16910628
20.

[Escitalopram for treatment of major depressive disorder in adults].

Llorca PM, Brousse G, Schwan R.

Encephale. 2005 Jul-Aug;31(4 Pt 1):490-501. Review. French.

PMID:
16389716
Items per page

Supplemental Content

Support Center